If you take away one thing from this article, let it be this: the standard lipid panel is incomplete. It measures the cholesterol content of your lipoproteins, but it does not measure the number of atherogenic particles circulating in your blood. That particle count, measured by apolipoprotein B, or ApoB, is the single best predictor of cardiovascular risk. And it is almost never tested.
The reason particle count matters more than cholesterol content is that atherogenicity is driven by the number of particles that can enter the arterial wall, not by how much cholesterol each one carries. Small, dense LDL particles are particularly dangerous because they penetrate the endothelium more easily and bind more readily to proteoglycans in the intima. A standard lipid panel reports LDL cholesterol, which is a calculated value that assumes each LDL particle carries a fixed amount of cholesterol. In reality, LDL particles vary widely in cholesterol content. A person with many cholesterol-poor LDL particles can have a normal LDL cholesterol but a dangerously high particle count. ApoB captures that particle count directly, which is why it outperforms LDL in every major outcome study.
This isn't a niche issue for researchers: it's a practical, everyday problem for AAS users who rely on blood work to manage their health. If your licensed medical professional only orders standard lipids, you're flying blind on cardiovascular risk.
Every "bad" lipoprotein particle in your blood, VLDL, IDL, LDL, and Lp(a), contains exactly one ApoB molecule. So when you measure ApoB, you get a direct count of every atherogenic particle in circulation. It's the closest thing we have to a "cardiac body count.
This one-to-one relationship between ApoB and atherogenic particles is not just a theoretical nicety. It means that an ApoB measurement of 100 mg/dL corresponds to roughly 1000 nmol/L of particles, and higher ApoB tracks with meaningfully higher cardiovascular risk in a dose-dependent way, independent of what LDL cholesterol shows. For AAS users, who often have elevated particle numbers due to androgen-induced changes in hepatic lipase activity and LDL receptor expression, this direct count is indispensable. A calculated LDL of 130 mg/dL might reflect either 1300 large buoyant particles or 1800 small dense particles. Only ApoB tells you which scenario you are in. That distinction changes your treatment threshold and your risk assessment.
🚚Imagine two delivery trucks carrying the same total load. One truck carries 100 small boxes. The other carries 10 large boxes. The total cargo weight is identical, but the number of vehicles on the road is very different. ApoB counts the vehicles. LDL cholesterol weighs the cargo. Cardiovascular risk is driven by the number of vehicles, not the cargo weight.
— The delivery truck analogy
This distinction matters enormously for AAS users. Androgenic compounds alter both the size and the number of LDL particles. Some users develop many small, dense LDL particles, the most atherogenic kind, while their calculated LDL cholesterol appears only mildly elevated. Standard LDL would tell you "borderline risk." ApoB would tell you "this is dangerous.
The type of androgen you use matters for this particle shift. Oral AAS like stanozolol and oxandrolone are more likely to produce small dense LDL because they cause a pronounced drop in HDL and increase hepatic lipase activity, which remodels LDL into smaller particles. Injectable testosterone at moderate doses tends to have a milder effect, but supraphysiological doses still shift the particle profile toward the atherogenic end. If you're using an oral compound and your ApoB is climbing, compound choice is one of the levers worth discussing with whoever manages your protocol — a step many users overlook when they only look at LDL cholesterol, which may not change much even as particle number rises.
Standard Lipid Panel vs. Complete Panel + ApoB
| Marker | Standard Panel | Complete Panel |
|---|---|---|
| Total Cholesterol | Yes | Yes |
| HDL | Yes | Yes |
| LDL (calculated) | Yes | Yes |
| LDL (direct) | No | Yes |
| Triglycerides | Yes | Yes |
| ApoB | No | Yes |
| Lp(a) | No | Recommended |
| Non-HDL cholesterol | Calculated | Calculated |
| Particle count | Unknown | Known via ApoB |
| Small dense LDL | Unknown | Inferred from ApoB |
Apolipoprotein B (ApoB)
LDL Cholesterol (Calculated)
HDL Cholesterol
Based on current evidence and expert consensus for individuals with elevated cardiovascular risk, which includes AAS users, here are the ApoB targets you should aim for:
Below 90
mg/dL (0.9 g/L)
A low-risk reading — worth rechecking every 8-12 weeks on cycle to confirm it's holding.
90-109
mg/dL (0.9-1.1 g/L)
This level is generally tolerated by AAS users on cycle — keep an eye on it with each panel, and mention a rising trend to a licensed medical professional rather than waiting for it to cross into the next tier.
110-129
mg/dL (1.1-1.3 g/L)
Worth a real conversation with a licensed medical professional about next steps — lipid-lowering medication, omega-3 intake, and compound or dose changes are all on the table, but which combination makes sense depends on your full picture, not this number alone.
130+
mg/dL (1.3+ g/L)
Get a medical consult before you do anything else. This level of elevation calls for aggressive management, and whether that includes ending the cycle is a decision to make with a licensed medical professional, not on your own.
Cost and Convention
A standard lipid panel costs around $15-30, and adding ApoB costs another $20-40. Many insurance plans consider it 'experimental' or not medically necessary for routine screening, so most licensed medical professionals simply don't order it. The standard guidelines, ATP III and ESC, have only recently begun to emphasize ApoB as a primary target.
If your insurance refuses to cover ApoB, you have options. Direct-to-consumer labs like LabCorp and Quest offer ApoB as a standalone test for $20 to $40, and you can order it without a licensed medical professional's visit. Some advanced lipid panels, such as the NMR LipoProfile, include ApoB along with LDL particle number and size, but they cost more. A cheaper alternative is to ask for a standard lipid panel plus ApoB, which gives you the key information without the extra cost of particle sizing. You can also use a health savings account (HSA) or flexible spending account (FSA) to pay for it. The point is that the barrier is not cost or access; it is simply knowing to ask.
The result is a system where clinicians manage cardiovascular risk using a proxy (LDL) while the actual risk metric (ApoB) sits on the shelf. For the general population, this gap may be acceptable, but for AAS users, who already have elevated cardiovascular risk, it is a dangerous blind spot.
LDL Alone Can Be Misleading
Consider a real example: after 3 months on 500 mg testosterone per week, a user has LDL at 150 mg/dL (borderline high) with HDL at 28 mg/dL (low). A standard assessment would say: moderate dyslipidemia. Nothing alarming.
But the same user's ApoB might be 130 mg/dL, which places them in the high-risk category. Their LDL number says "moderate concern" while their ApoB says "real danger." Without ApoB, this user walks away from their licensed medical professional's appointment reassured and under-informed. The LDL number is a guess. The ApoB is the truth.
Discordance between LDL and ApoB is not rare. Analyses from cohorts like the Multi-Ethnic Study of Atherosclerosis (MESA) have identified a meaningful subgroup with a "normal" LDL but an elevated ApoB, and that group carries higher coronary event risk than people whose LDL and ApoB agree. For AAS users, the discordance rate is likely higher because of the frequent presence of hypertriglyceridemia and low HDL. If your LDL looks unremarkable but your ApoB is meaningfully elevated, that discordance itself is worth bringing to a licensed medical professional — it can justify treatment your LDL alone wouldn't, but what that treatment is remains their call. Do not wait for LDL to catch up. ApoB is the leading indicator.
Getting ApoB onto your panel is simpler than you'd expect. Here's exactly how to do it.
Ask a Licensed Medical Professional
Add apolipoprotein B to your next lab requisition, and be sure to use the full name so it isn't confused with ApoA1, a different marker.
Push Back If Needed
If your licensed medical professional pushes back, explain plainly that you're using performance hormones and require a comprehensive cardiovascular risk assessment, not routine screening.
Self-Order
A direct-to-consumer lab like LabCorp or Quest gets you the same numbers without the runaround. The $20-40 cost is trivial next to the value of knowing your true risk.
ApoB vs. LDL Discordance
In roughly 20% of individuals, ApoB and LDL give different risk signals. This is called discordance, and it is more common in insulin-resistant and hypertriglyceridemic individuals — two groups with significant overlap with AAS users.
When ApoB and LDL disagree, the evidence consistently shows ApoB is the better predictor of outcomes. A 2024 review in the Journal of the American College of Cardiology laid out the case for ApoB as a primary clinical target, concluding the evidence is strong enough for routine use, not just research settings. If you can only afford one advanced lipid test, make it ApoB.
The evidence for ApoB superiority is not limited to one study. The INTERHEART study, which included over 12,000 cases of myocardial infarction, found that the ApoB/ApoA1 ratio was the strongest lipid predictor of heart attack risk, outperforming LDL cholesterol. The AMORIS study, with over 175,000 subjects, showed that ApoB was more closely associated with fatal myocardial infarction than LDL. In a meta-analysis of 12 statin trials, on-treatment ApoB levels were more predictive of residual risk than LDL. For AAS users, who often have low HDL and high triglycerides, the gap between LDL and ApoB widens. If your licensed medical professional only orders LDL, you are missing the metric that matters most for your specific physiology.
The mechanism behind discordance is often triglyceride-rich lipoproteins. When triglycerides are elevated, VLDL particles carry more cholesterol, and the calculated LDL cholesterol underestimates the true number of atherogenic particles. This is why ApoB is the preferred marker in patients with metabolic syndrome, diabetes, or hypertriglyceridemia, all of which are common in AAS users. In a person with triglycerides above 200 mg/dL, the Friedewald equation becomes unreliable, and even the newer Martin-Hopkins calculation has limitations. ApoB is measured directly and is not affected by triglyceride levels. If your triglycerides are high, you should insist on ApoB rather than relying on calculated LDL, because the latter will give you a false sense of security.
Also Add: Non-HDL Cholesterol and Lp(a)
When ApoB isn't available, non-HDL cholesterol (total minus HDL) is a reasonable proxy. It captures cholesterol from all atherogenic particles, not just LDL. It's not as accurate as ApoB, but it's better than calculated LDL alone.
Lipoprotein(a) or Lp(a) is a genetically determined risk factor that does not change significantly with lifestyle or most medications. Test it once in your life: if it is elevated, you need more aggressive lipid management regardless of your other numbers.
If you cannot get ApoB, non-HDL cholesterol is a workable substitute. Non-HDL is calculated as total cholesterol minus HDL, and it captures cholesterol from all atherogenic particles, including VLDL and IDL. The target for non-HDL is typically 30 mg/dL higher than the LDL target. For AAS users aiming for an LDL below 90 mg/dL, that means a non-HDL below 120 mg/dL. Non-HDL is more accurate than calculated LDL in hypertriglyceridemic states, but it still does not account for particle size or number. It is a reasonable fallback, but it is not a replacement. If your non-HDL is above 120 mg/dL, you should push harder to get ApoB measured, because the particle count could be even more concerning than the cholesterol load suggests.